Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.43
$0.252.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.32% | 15.01% | -1.99% | 1.33% | -9.67% |
| Total Depreciation and Amortization | -14.13% | -11.83% | -7.29% | 7.57% | 28.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.83% | 3.31% | 3.35% | 3.85% | 4.49% |
| Change in Net Operating Assets | -144.34% | -366.67% | -2.02% | 45.97% | 65.79% |
| Cash from Operations | 182.52% | -7.13% | -1.83% | 8.71% | 1.68% |
| Capital Expenditure | 76.56% | 87.44% | 78.29% | 80.54% | 55.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -260.92% | -199.73% | -180.66% | -128.41% | -56.03% |
| Cash from Investing | -265.21% | -201.44% | -182.28% | -129.40% | -56.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,252.13% | 147.31% | 201.64% | 185.82% | -80.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,252.13% | 147.31% | 201.64% | 185.82% | -80.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 920.39% | -181.19% | -152.18% | -98.86% | -111.07% |